

ASX Announcement

15 August 2024

OncoSil Medical Reports Significant Growth in Commercial Treatment Sales in Q4 FY24

Key Highlights

- ✓ The number of OncoSil™ doses used in commercial treatments in Q4 FY24 increased by 78% compared to Q4 FY23.
- ✓ Continued market expansion and positive reception of the OncoSil™ device across key markets.

Sydney, Australia – 15 August 2024: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce a substantial increase in the number of doses used in commercial treatments, reflecting the growing adoption of the OncoSil™ device in clinical practice.

In Q4 FY24, the number of doses used at commercial treatments increased by 78% compared to Q4 FY23, and was 2.7 times of the average volume for the first three quarters of FY24. This substantial growth highlights the success of our strategic initiatives focused on expanding market reach and enhancing access to innovative cancer treatment solutions. The significant surge in demand demonstrates the strong confidence healthcare providers have in the OncoSil™ device as an essential tool in the fight against pancreatic cancer.

OncoSil remains committed to delivering cutting-edge medical technology to improve patient outcomes globally. We are excited about the momentum we have built and look forward to continuing this trajectory in the current fiscal year.

OncoSil Medical CEO & Managing Director, Nigel Lange, said: "This remarkable growth in sales and commercial treatments clearly demonstrates the efficacy of the OncoSil™ device and the strong trust our healthcare partners have in our technology. Our focus on delivering innovative solutions for patients battling pancreatic cancer is producing significant and meaningful results. Moving forward, we are committed to not only sustaining this momentum but also becoming even more aggressive in our market penetration and growth strategies, ensuring that more patients around the world can benefit from our cutting-edge treatment options."

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

<p>Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043</p>	<p>Mr. Christian Dal Cin Acclime CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254</p>	<p>Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699</p>
---	---	--

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient’s pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References:

1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>